(-) Idenix Pharmaceuticals provides update on IDX184 and IDX19368 development programs (Idenix) - Feb 4, 2013 - "Idenix...announced...not to continue its clinical development program for IDX184...phase IIb testing for the treatment of...HCV infection, or to continue its development of IDX19368...for which the Company had previously filed an IND but had not initiated patient dosing."
Discontinued • Hepatitis C Virus
|
|
Related news:
http://blogs.wsj.com/marketbeat/2013/02/05/stocks-to-watch-yum-brands-idenix-pharma-opexa-therapeutics/?KEYWORDS=hepatitis+c
|